Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

News Conference News HFSA 2025

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

Yael L. Maxwell

October 01, 2025

News Daily News

LAAO May Be an Option for Anticoagulated AF Patients With Breakthrough Stroke

Todd Neale

September 30, 2025

News Conference News HFSA 2025

Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74

Yael L. Maxwell

September 30, 2025

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

News Conference News THT 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Michael O'Riordan

March 06, 2024

News Conference News AHA 2023

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

Caitlin E. Cox

November 14, 2023

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HCM3

News Conference News AHA 2023

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HM3

Shelley Wood

November 11, 2023

News Conference News ESC 2023

IV Iron in HF Misses (Again) in HEART-FID, but Meta-analysis Sees a Role

Shelley Wood

August 26, 2023

News Conference News AHA 2022

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

Todd Neale

November 07, 2022

News Conference News AHA 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

Shelley Wood

November 05, 2022

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

L.A. McKeown

April 08, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Daily News

Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited

Michael O'Riordan

August 03, 2021

Advertisement

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

LAAO May Be an Option for Anticoagulated AF Patients With Breakthrough Stroke

Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HM3

IV Iron in HF Misses (Again) in HEART-FID, but Meta-analysis Sees a Role

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content